Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Diagnosing multiple myeloma is notoriously difficult- many people live with bone or nerve pain for months before they are formally diagnosed with multiple myeloma. Because the average age of the newly diagnosed multiple myeloma patient is 70 according to research, myeloma is considered to be a cancer of the elderly.
Like all cancers, the earlier you diagnose myeloma, the better your prognosis will be. Be sure to learn Multiple Myeloma – Signs and Symptoms in order to identify possible symptoms of either pre-myeloma or full multiple myeloma.
The most important thing to remember about multiple myeloma diagnostic criteria is that oncology continues to learn more about our incurable blood cancer and therefore improve their ability to diagnose multiple myeloma at the correct stage to determine your risk of progression.
An example of this is the multiple myeloma diagnostic criteria called SLiM CRAB.
Conventional oncology has taken the basic multiple myeloma diagnostic criteria of-
And added risk of progression by determining that newly diagnosed myeloma patients with:
I think it is helpful to think about some of the big picture issues so I have written about the larger issues the come with a diagnosis of multiple myeloma.
Please read the “Treatment of Multiple Myeloma: Cure vs. Control” linked below. If you understand your diagnostic criteria, you will be able to apply the ideas discussed in the cure vs. control article and therefore understand your therapy plan to treat your multiple myeloma.
Controlling MM combined with evidence-based complementary and integrative therapies I believe, allows the best prognosis for your multiple myeloma.
Do you understand your results? It’s normal to have a lot of questions — or to be confused about where to start.
Scroll down the page, post a question or comment and I will reply to you ASAP.
Hang in there,
“Although not often openly acknowledged, “cure vs control” is the dominant philosophical difference behind many of the strategies, trials, and debates related to the management of myeloma. Should we treat patients with myeloma with multidrug, multitransplant combinations with the goal of potentially curing a subset of patients, recognizing that the risk of adverse events and effect on quality of life will be substantial? Or should we address myeloma as a chronic incurable condition with the goal of disease control, using the least toxic regimens, emphasizing a balance between efficacy and quality of life, and reserving more aggressive therapy for later?
To be sure, if cure were known to be possible (with a reasonable probability) in myeloma, it would undoubtedly be the preferred therapeutic goal of most patients and physicians. But this is not the case. Myeloma is generally not considered a curable disease…
Cure vs control is debated because the strategies currently being tested are not truly curative but rather are intended to maximize response rates in the hope that they will translate into an operational cure for a subset of patients…
In the 1990s, high-dose therapy with autologous stem cell transplant (ASCT) became part of standard practice when it was found to prolong survival compared with conventional chemotherapy.5–7Subsequently, bisphosphonates were found to be effective in decreasing the incidence of bone lesions.8,9
In fact, it is not uncommon to find that well-meaning investigators interpret the same clinical trial data in opposite ways because they ascribe to different philosophies (cure vs control).19 Although this commentary focuses on myeloma, the cure-vs-control debate may be relevant to other similar chronic malignant and nonmalignant disorders.20–28″
“IMWG initially added 3 new biomarkers, among other modifications, to the previously established criteria, which have become known as CRAB, which features elevated calcium levels (C), renal failure (R), anemia (A), and bone lesions (B)…
The new and current diagnostic and staging criteria, known as SLiM CRAB, now include the following: 60% or more clonal plasma cells (S), light chains (Li), and MRI (M).
It has been observed that patients with: